)
Visual
test
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (IRWD) investor relations material
Ironwood Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary10 Nov, 2025
Executive summary
Achieved strong Q3 2025 results, with 40% year-over-year growth in LINZESS U.S. net sales and robust prescription demand, supported by improved net pricing and expanded indications.
FDA approved LINZESS for children 7+ with IBS-C in November 2025, expanding its clinical utility.
Generated GAAP net income of $40.1M and adjusted EBITDA of $81.8M in Q3 2025.
Advanced apraglutide program toward a Phase 3 trial for short bowel syndrome, with trial initiation expected in H1 2026, pending FDA alignment.
Ongoing review of strategic alternatives with Goldman Sachs to maximize shareholder value.
Financial highlights
Q3 2025 total revenue was $122.1M, up from $91.6M in Q3 2024.
LINZESS U.S. net sales reached $315M, a 40% increase year-over-year.
GAAP net income: $40.1M; adjusted EBITDA: $81.8M.
Basic EPS: $0.25; diluted EPS: $0.23.
Ended Q3 2025 with $140.4M in cash and cash equivalents.
Outlook and guidance
Raised FY 2025 LINZESS U.S. net sales guidance to $860–$890M.
Increased total revenue guidance to $290–$310M and adjusted EBITDA to >$135M.
Expects strong Q4 LINZESS demand, but with reduced net price due to rebate reserves and Medicare Part D redesign.
Cash, expected operating inflows, and borrowing capacity projected to cover operating needs for at least the next twelve months.
Strategic alternatives, including potential transactions, are under review to maximize shareholder value.
Detail Q4 LINZESS net price reduction factors
Apraglutide Phase 3 trial design specifics
Impact of strategic reorganization on costs
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 055550
Net income up 11.7% YoY, shareholder returns at 50.2%, CET1 ratio at 13.33%. - RM
Record 2025 net income, originations, and efficiency set up strong 2026 growth outlook. - KPIL
27% YOY revenue growth, strong profit and order book, and improved debt metrics drive outlook. - FSV
Annual revenues rose 5% to $5.50B, led by Residential growth and improved profitability. - HEXT
Revenue up 7.6% YoY, margin expands, and AI and acquisitions drive future growth. - 4188
Net income surged on discontinued operations gains, but outlook cut due to restructuring costs. - 021240
Record-high profits and strong rental growth, with overseas expansion led by Malaysia and Thailand. - 021240Record revenue and profit growth in 2Q'25, led by robust domestic and overseas performance.
- 021240Record-high revenue and net profit in 3Q'24, driven by robust rental growth and overseas expansion.
- 021240Record revenue and profit, with strong growth in rental accounts and overseas markets.
Next Ironwood Pharmaceuticals earnings date
Q4 202517 Feb, 2026
Ironwood Pharmaceuticals
Next Ironwood Pharmaceuticals earnings date
Q4 202517 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ironwood Pharmaceuticals Inc is a gastrointestinal-focused healthcare company that develops and markets therapies for chronic digestive diseases. The company’s product portfolio includes treatments for irritable bowel syndrome and other gastrointestinal conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage